By reducing its virulence, it has become the new ally to continue stopping the coronavirus. It’s about the fluvoxamina, a drug commonly used to treat depression and which, according to a study published in the scientific journal The Lancet, reduces the risk of prolonged hospitalizations.
” Fluvoxamine treatment among outpatients of high risk with COVID-19 reduced the need for hospitalization defined as retention or transfer of patients to hospitals, ‘he says.
Considered one of the oldest drugs in the class of selective serotonin reuptake inhibitors, fluvoxamine could be one of the solutions to avoid hospital collapses in unvaccinated populations.
Precisely, in a test carried out in Brazil where only half the population is vaccinated against the virus, 741 unvaccinated, symptomatic positive high-risk patients for COVID have been tested. From them, only 10.6% of those medicated with this drug remained more than six hours in the emergency room or hospitalized.
In a secondary analysis, it was also found that among the patients who received at least 80% of the doses of fluvoxamine, a single death. A cheap, widely available and effective therapy that shows us that science is beginning to advance faster than the virus.
Ricardo is a renowned author and journalist, known for his exceptional writing on top-news stories. He currently works as a writer at the 247 News Agency, where he is known for his ability to deliver breaking news and insightful analysis on the most pressing issues of the day.
